Madrigal Pharmaceuticals stock
MDGLNASDAQMadrigal Pharmaceuticals, Inc., HealthcareISIN US5588681057
34Score 34 out of 100, Weak
Price and trend
43 / 100
Price history
−20% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 14% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 29% below its 52-week high. Largest decline in 20 years: 98% (January 2013 to February 2016).
Chart figures for advanced users
- SMA 50$478.03
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$496.33
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$396.32
- The lowest closing price of the last twelve months.
- Resistance$602.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Madrigal Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $12.44B, is number 28 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $958.4M (up 432.1% year on year) and a loss of $288.28M.
- For fiscal 2026, analysts expect on average revenue of $1.58B (up 64.9%) and adjusted earnings per share of −$2.18.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 649 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $960.97M, financial debt $354.22M.Stability 57
Weaknesses
- DilutionShare count up 45% since 2020.Capital allocation 18
- Loss-makingLoss of $155.46M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$168.65M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 50.1% on the same quarter a year earlier. Revenue has grown strongly since 2024, at around 432% per year. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 94%, operating −31%, net −30%. Last 12 months: net −11%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 3 Nov 2026EPS reported $1.83 (expected −$0.86)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 63.8% since 15 Oct 2026.
- Earnings per share
- −$2.18+63.8%
- Revenue
- $1.58B+3.6%
- Earnings per share
- $7.03+23.0%
- Revenue
- $2.18B+3.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −14.5%Continues to expect steady patient adds and robust net sales growth, gross to net discount in the mid to high 30s; 2026 R&D roughly the same as 2025, SG&A higher.
“We also continue to effectively manage growth to net and continue to expect our growth to net discount to be in the mid to high 30s for this year. Taken together, these fundamentals support our expectation for continued steady patient adds and robust net sales growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $35.02M in total. 4 insiders sold, $12.26M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Baker Bros. Advisors LpPurchase
6 Nov 2026, Board
- Shares
- 76,140
- Price
- $384.32
- Value
- $29.26M
- Kelley Shannon TSale
6 Nov 2026, General Counsel
- Shares
- 1,077
- Price
- $400.00
- Value
- $430,800
- Baker Bros. Advisors LpPurchase
4 Nov 2026, Board
- Shares
- 15,666
- Price
- $367.71
- Value
- $5.76M
Show 7 more
- Sibold William JohnSale
11 Sept 2026, President and CEO
- Shares
- 5,221
- Price
- $542.39
- Value
- $2.83M
- Sibold William JohnSale
9 Sept 2026, President and CEO
- Shares
- 6,362
- Price
- $535.59
- Value
- $3.41M
- Kelley Shannon TSale
17 Aug 2026, General Counsel
- Shares
- 664
- Price
- $514.97
- Value
- $341,940
- Sibold William JohnSale
20 Jul 2026, President and CEO
- Shares
- 2,500
- Price
- $547.30
- Value
- $1.37M
- Soergel DavidSale
1 Jun 2026, Chief Medical Officer
- Shares
- 1,042
- Price
- $495.74
- Value
- $516,561
- Levy Richard SSale
22 May 2026, Board
- Shares
- 5,682
- Price
- $515.44
- Value
- $2.93M
- Soergel DavidSale
18 May 2026, Chief Medical Officer
- Shares
- 844
- Price
- $515.90
- Value
- $435,420
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Madrigal Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- BridgeBio PharmaBBIO $15.49B50
- Sichuan Kelun-Biotech Biopharmaceutical6990.HK $13.99B49
- Kymera TherapeuticsKYMR $13.5B45
- Summit TherapeuticsSMMT $13.27B39
- Pharmaron Beijing300759.SZ $12.15B58
- Financière de TubizeTUB.BR $11.9B50
- Halozyme TherapeuticsHALO $11.59B80
- Bio-TechneTECH $11.44B65
ETFs that hold Madrigal Pharmaceuticals
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.61% | 0.35% | €1.21B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.50% | 0.25% | €44.3M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.10% | 0.43% | €2.48B |
Show 5 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.06% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.01% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.01% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2010)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.